Undisclosed AMD Program

About Character Biosciences

Character Biosciences is a private, clinical-stage biotech company pioneering a data-driven approach to treat complex polygenic diseases. By integrating genomics, longitudinal clinical data, imaging, and AI, the company identifies patient subtypes and genetic drivers of disease progression to develop more precise therapeutics. The company has built a robust pipeline with candidates in Phase 1 for dry AMD and geographic atrophy, secured Series B funding from top-tier investors, and assembled a seasoned leadership team with expertise in drug discovery, data science, and clinical development.

About Mobius Scientific

Mobius Scientific is a private, preclinical-stage biotech company founded in 2015, targeting the large unmet need in retinal diseases like age-related macular degeneration. The company is developing a proprietary platform for targeted biologics delivery to treat the root cause of vision loss. Its strategy involves leveraging groundbreaking technology to create a new treatment paradigm for the retina and potentially other tissues. As a pre-revenue entity, its success hinges on advancing its platform through clinical validation and securing strategic partnerships or funding.

Therapeutic Areas

Other Age-Related Macular Degeneration (AMD) Drugs